A Phase 4 interventional study of Ropivacaine and 0.9 % NaCl in Cardiac Surgery, Coronary Artery Disease and Valvular Diseases, sponsored by Saint Petersburg State University, Russia. Recruiting at 2 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Saint Petersburg State University, Russia · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Coronary Artery Disease with a site in Russia — 16 open to participants now, 17 under way, none of them phase 3. Coronary Artery Disease · Russia.
Among the 26 studies in Coronary Artery Disease with a site in Russia, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 12 of the 16 other live ones, and was the 16th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →16 of the 26 studies in Coronary Artery Disease with a site in Russia are open now. Recruiting first, the newest first:
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · Sites in Russia
Ages 18+
Tomsk Cardiology Research Institute · Sites in Russia
Ages 18+ · Women only
Research Institute of Geroprotective Technologies · Sites in Russia
Ages 50–80
Lomonosov Moscow State University Medical Research and Educational Center · Sites in Russia
Ages 40–65 · Men only
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is close to the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 113 across the 14 interventional studies, 445 across the 12 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 26 have an industry lead sponsor. The 10 most frequent:
Saint Petersburg State University, Russia is the lead sponsor of 34 studies on the registry; 14 are open to participants now.
Saint Petersburg State University, Russia has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Coronary Artery Disease with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770349Tomsk National Research Medical Center of the Russian Academy of SciencesUltrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure | 2026-11 |
| NCT04347200National Medical Research Center for Cardiology, Ministry of Health of Russian FederationREGistry of Long-term AnTithrombotic TherApy-1 | 2026-12-31 |
| NCT04347187National Medical Research Center for Cardiology, Ministry of Health of Russian FederationREGistry of Long-term AnTithrombotic TherApy-2 | 2026-12-31 |
| NCT07711106Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health"Expert IVUS-Eye" vs. IVUS-guided Left Main Bifurcation PCI | 2027-01-01 |
| NCT07480915Tomsk National Research Medical Center of the Russian Academy of SciencesRisk Stratification of MACE in Heart Failure Patients Who Undergoing CABG | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 26 studies in Coronary Artery Disease with a site in Russia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
For many patients, a primary source of postoperative pain following cardiac surgery is the presence of pleural drains, which the surgeon places at the end of the operation and maintains for 1 to 3 days. One promising method of pain management after cardiac surgery is interpleural analgesia, particularly when traditional analgesic methods, such as systemic opioids or epidural anesthesia, may be limited due to the risk of complications. Interpleural analgesia involves the introduction of local anesthetics directly into the pleural cavity through drainage tubes placed after cardiac surgery. This method targets pain receptors in the chest area, providing effective analgesia without significant systemic effects. Several clinical studies have confirmed the safety and efficacy of intrapleural administration of anesthetics after thoracic surgery. The aim of this randomised double-blind placebo controlled study is to test the hypothesis that, in patients after cardiac surgery, the quality of recovery from anesthesia with intrapleural use of ropivacaine is superior to that with a placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ropivacaine
Drug: 0.9 % NaCl
The patient will receive 0.2% ropivacaine (20.0 ml) into the pleural cavity intraoperatively before sternal closure. A continuous infusion of 0.2% ropivacaine will be administered through a microcatheter into the drained pleural cavity, with titration of the infusion rate. The initial infusion rate is set at 10 ml/hour.
The patient will receive 20.0 ml of a 0.9% sodium chloride solution into the pleural cavity intraoperatively, prior to sternal closure. A continuous infusion of 0.9% sodium chloride solution will then be administered through a microcatheter into the drained pleural cavity. The initial infusion rate is set at 10 ml/hour.
Quality of recovery after anesthesia (QoR15) questionnaire
ranged from 0 to 150 points, where 0 is the worst and 150 is the best.
Time frame: 24 hours after surgery
pO2/FiO2 ratio
Time frame: 6, 12, 24 hours after surgery
Morphine equvalents, mg/day
Time frame: 24 hours after surgery
Pain assessed by Visual analog scale
from 0 to 10 when 0 is worst and 10 is best
Time frame: 6, 12, 24, 48 hours
Postoperative complications
Composite (myocardial infarction, stroke, delirium, new onset atrial fibrillation, infections)
Time frame: at discharge (assessed up to 30 days)
Hospital mortality
Death during hospitalisation
Time frame: At discharge (assessed up to 6 months)
Length of hospitalisation
Number of days in hospital during initial hospitalisation
Time frame: At discharge (assessed up to 6 months)
Sternal wound dehiscence
Time frame: At discharge (assessed up to 6 months)
Plan to share: Yes — IPD will be available by the reasonable request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.
Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 23 months is below that.
Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Saint Petersburg State University, Russia